Fujian Wanchen Biotechnology Co., Ltd engages in the research and development, cultivation, production, and sale of edible fungi in China. It offers flammulina velutipes; and crab-flavored, white jade, seafood mushrooms, etc. The company was founded in 2011 and is based in Zhangpu, China.
Fujian Wanchen Biotechnology Co. Ltd (300972) - Total Assets
Latest total assets as of March 2025: CN¥6.78 Billion CNY
Based on the latest financial reports, Fujian Wanchen Biotechnology Co. Ltd (300972) holds total assets worth CN¥6.78 Billion CNY as of March 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Fujian Wanchen Biotechnology Co. Ltd - Total Assets Trend (2019–2024)
This chart illustrates how Fujian Wanchen Biotechnology Co. Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Fujian Wanchen Biotechnology Co. Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Fujian Wanchen Biotechnology Co. Ltd's total assets of CN¥6.78 Billion consist of 79.6% current assets and 20.4% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 32.8% |
| Accounts Receivable | CN¥18.47 Million | 0.3% |
| Inventory | CN¥2.14 Billion | 29.5% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥59.52 Million | 0.8% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2019–2024)
This chart illustrates how Fujian Wanchen Biotechnology Co. Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Fujian Wanchen Biotechnology Co. Ltd's current assets represent 79.6% of total assets in 2024, an increase from 11.3% in 2019.
- Cash Position: Cash and equivalents constituted 32.8% of total assets in 2024, up from 4.1% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 8.0% in 2019.
- Asset Diversification: The largest asset category is inventory at 29.5% of total assets.
Fujian Wanchen Biotechnology Co. Ltd Competitors by Total Assets
Key competitors of Fujian Wanchen Biotechnology Co. Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Dongrui Food Group Co Ltd
SHE:001201
|
China | CN¥6.20 Billion |
|
ShenZhen Kondarl Group Co Ltd
SHE:000048
|
China | CN¥10.89 Billion |
|
Guangdong Guanghong Holdings Co Ltd
SHE:000529
|
China | CN¥6.42 Billion |
|
Hunan Zhenghong Science and Technology Develop Co Ltd
SHE:000702
|
China | CN¥697.07 Million |
|
Hefei Fengle Seed Co Ltd
SHE:000713
|
China | CN¥3.32 Billion |
|
Luoniushan Co Ltd
SHE:000735
|
China | CN¥10.16 Billion |
|
New Hope Liuhe Co Ltd
SHE:000876
|
China | CN¥117.94 Billion |
|
Yuan Longping High-tech Agriculture Co Ltd
SHE:000998
|
China | CN¥24.29 Billion |
Fujian Wanchen Biotechnology Co. Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Strong asset utilization - Fujian Wanchen Biotechnology Co. Ltd generates 4.46x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Moderate ROA - For every $100 in assets, Fujian Wanchen Biotechnology Co. Ltd generates $ 4.05 in net profit.
Fujian Wanchen Biotechnology Co. Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.28 | 1.02 | 1.80 |
| Quick Ratio | 0.93 | 0.77 | 1.45 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥1.15 Billion | CN¥ 48.61 Million | CN¥ 131.10 Million |
Fujian Wanchen Biotechnology Co. Ltd - Advanced Valuation Insights
This section examines the relationship between Fujian Wanchen Biotechnology Co. Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 24.93 |
| Latest Market Cap to Assets Ratio | 0.28 |
| Asset Growth Rate (YoY) | 84.8% |
| Total Assets | CN¥7.25 Billion |
| Market Capitalization | $2.02 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Fujian Wanchen Biotechnology Co. Ltd's assets below their book value (0.28 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Fujian Wanchen Biotechnology Co. Ltd's assets grew by 84.8% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Fujian Wanchen Biotechnology Co. Ltd (2019–2024)
The table below shows the annual total assets of Fujian Wanchen Biotechnology Co. Ltd from 2019 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥7.25 Billion | +84.78% |
| 2023-12-31 | CN¥3.93 Billion | +226.80% |
| 2022-12-31 | CN¥1.20 Billion | +39.15% |
| 2021-12-31 | CN¥863.18 Million | +31.06% |
| 2020-12-31 | CN¥658.59 Million | +0.45% |
| 2019-12-31 | CN¥655.63 Million | -- |